Mereo BioPharma (MREO) Return on Sales (2023 - 2026)

Mereo BioPharma (MREO) posted quarterly Return on Sales of 1.05% for Q4 2025, little changed quarter-over-quarter from 1.05% in Q3 2025.

Mereo BioPharma (MREO) Return on Sales (2023 - 2026) Analysis & Trends

Mereo BioPharma (MREO) has reported Return on Sales for 3 consecutive years, with 1.05% the latest figure, recorded in Q4 2025.

In Q4 2025, Return on Sales changed N/A year-over-year to 1.05%; the TTM figure through Dec 2025 stood at 1.05% (changed N/A YoY), while the FY2025 annual figure was 1.05%, changed N/A from the prior year.
Return on Sales was little changed at 1.05% in Q4 2025 per MREO's latest filing, from 1.05% in the prior quarter.
Across five years, Return on Sales topped out at 0.02% in Q1 2024 and bottomed at 1.05% in Q3 2025.
Historically, Return on Sales has averaged 0.47% across 3 years, with a median of 0.37% in 2024.
On a YoY basis, Return on Sales climbed as much as 8 bps in 2025 and fell as far as 60 bps in 2025.
Mereo BioPharma's Return on Sales stood at 0.09% in 2023, then slumped by 397 bps to 0.45% in 2024, then tumbled by 131 bps to 1.05% in 2025.
Business Quant data shows MREO's Return on Sales at 1.05% in Q4 2025, 1.05% in Q3 2025, and 0.29% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Mereo BioPharma	47.39 Mn	47.39 Mn	-	-0.77%

Download Data